Ready for Takeoff? MEI Pharma Inc (NASDAQ:MEIP)

MEI Pharma Inc (NASDAQ:MEIP) is trading in a very narrow range in early session on Thursday. The stock has been witnessing a weak trend since over the past month with a fall of around 7%.

Major Trigger:

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

Key Highlights:

  • announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta (“PI3K”) inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021.

Market Reaction

As of 11:11, MEIP stock down by 0.16% to $3.15 with more than 82K shares traded hands, compared to its average volume of 652K shares. The stock has moved within a range of $3.1150 – 3.1900 after opening the trade at $3.19.

Technical Indicators

CCI20126.7273BuyChaikin Money Flow-0.1512Sell
MACD-0.0445SellMoney Flow Index75.6859Buy
STOCH (14,3)90.1961OverBoughtSTOCH RSI1.0000OverBought
UO61.3673BuyWilliams %R-9.8039OverBought

Related Posts

About The Author